AI/ML in Drug Development

ACRO’s AI/ML Committee brings together member company subject matter experts engaged in the development and use of AI/ML tools in the design, conduct, oversight, and analysis of clinical trials.

Thought Leadership

ACRO’s Artificial Intelligence/Machine Learning Committee produced the following Principles Statement in December 2023. The committee represents the industry to regulators and policymakers considering regulation and legislation that could impact the use of AI/ML in drug development. 

ACRO Artificial Intelligence & Machine Learning Principles Statement

Scroll to Top